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Abstract  24 
Visceral leishmaniasis is a neglected tropical disease, which causes significant morbidity and 25 
mortality worldwide. Characterising the pharmacokinetics and pharmacodynamics of anti-26 
leishmanial drugs in pre-clinical models is important for drug development and use. Here we 27 
investigated the pharmacodynamics and drug distribution of AmBisome® in L. donovani 28 
infected BALB/c mice at three different dose levels and two different time points after 29 
infection. We additionally compared drug levels in plasma, liver and spleen in infected and 30 
uninfected BALB/c mice over time. At the highest administered dose of 10 mg/kg AmBisome® 31 
>90% parasite inhibition was observed within 2 days after drug administration, consistent with 32 
drug distribution from blood to tissue within 24 hours and a fast rate of kill. Decreased drug 33 
potency was observed in the spleen when AmBisome® was administered on day 35 after 34 
infection, compared to day 14 after infection. Amphotericin B concentrations and total drug 35 
amounts per organ were lower in liver and spleen when AmBisome® was administered at the 36 
advanced stage of infection and when compared to uninfected BALB/c mice. However, the 37 
magnitude of difference was lower when total drug amounts per organ were estimated. 38 
Differences were also noted in drug distribution to L. donovani infected livers and spleens. 39 
Taken together our data suggests that organ enlargement and other pathophysiological factors 40 
cause infection- and organ-specific drug distribution and elimination after administration of 41 
single dose AmBisome® to L. donovani infected mice. Plasma levels were not reflective of 42 
changes in drug levels in tissues.   43 
 44 
 45 
 46 
 47 
 48 
 49 
INTRODUCTION 50 
Visceral leishmaniasis (VL) is a vector-borne neglected tropical disease (NTD) caused by 51 
protozoan parasites of the genus Leishmania. VL has a high mortality rate if untreated. Current 52 
estimates suggest 200 000 – 400 000 cases and 20 000 – 40 000 deaths per year worldwide 53 
with over 90% of cases occurring in India, Bangladesh, Sudan, South Sudan, Brazil and 54 
Ethiopia (1).  55 
Major clinical manifestations of disease are fever, enlargement of the liver and spleen, weight 56 
loss and pancytopenia. Available treatment options include pentavalent antimonials, 57 
paromomycin in combination with pentavalent antimony (in East Africa), miltefosine and 58 
amphotericin B in different formulations (2). Liposomal amphotericin B (AmBisome®) has 59 
emerged as the preferred treatment for VL in Europe and the US (3) and South Asia (2). In 60 
India a cure rate of 95.7% was achieved with a single infusion of 10 mg/kg of AmBisome® in 61 
a trial carried out at an urban referral centre (4). Feasibility of this treatment regime was 62 
confirmed in a rural setting in Bangladesh at primary health care level (5). Single-dose 63 
AmBisome® was also one component in recently trialled short-course multidrug treatment 64 
regimens for VL in India (6).  65 
AmBisome® was initially developed to improve efficacy and reduce toxicity of amphotericin 66 
B as an anti-fungal agent. Its favourable therapeutic index is attributed to prolonged circulation 67 
times due to a small liposome size, allowing distribution to tissues, and a tight association of 68 
amphotericin B with the liposome bilayer, providing stability under physiological conditions 69 
(7). AmBisome® also remains the anti-leishmanial agent with the widest therapeutic window 70 
for treatment of VL (3).  71 
Earlier studies have established the pre-clinical pharmacokinetics of AmBisome® in mice, rats, 72 
rabbits and dogs (7, 8). In addition, a comparative, single time-point biodistribution study in L. 73 
donovani infected and uninfected BALB/c mice showed that amphotericin B concentrations in 74 
liver and spleen were lower in infected mice after intravenous administration of AmBisome® 75 
(9). A separate study showed that AmBisome®, when administered as single dose to L. 76 
donovani infected BALB/c mice, was less effective in the chronic stage of infection compared 77 
to the acute stage (10). In anti-infective therapy with drugs that directly kill pathogens, such as 78 
amphotericin B, drug efficacy is driven by infection-site specific drug concentrations (11, 12). 79 
We therefore hypothesised that the decrease in potency of AmBisome® observed in chronic 80 
experimental VL (EVL) is linked to a decrease in organ-specific drug concentrations associated 81 
with progression of infection. Here we show that i) decreased potency of AmBisome® during 82 
progressive EVL is most pronounced in the spleen, ii) total drug amounts in liver and spleen 83 
progressively decrease during EVL, iii) organ-specific drug distribution and elimination 84 
patterns occur in EVL and iv) changes in drug levels in tissues are not reflected in the blood 85 
compartment.    86 
 87 
MATERIALS AND METHODS 88 
Drugs and reagents. AmBisome® was purchased from Gilead (Cambridge, UK). The powder 89 
was reconstituted in sterile water following the manufacturer's directions and further dilutions 90 
prepared in 5% glucose. Amphotericin B (VETRANAL™ analytical standard), tolbutamide, 91 
dimethyl sulfoxide (DMSO) and sodium dodecyl sulphate (SDS) were obtained from Sigma, 92 
UK, and heparin from John Bell & Croyden, UK. Methanol (HPLC grade), 0.1% (v/v) formic 93 
acid in water (LC-MS grade) and water (LC-MS grade) were purchased from Fisher Scientific 94 
UK Ltd, UK. 95 
 96 
In vivo experiments and treatment. Female BALB/c (Charles River, UK) and Rag-1 (B6) 97 
K.O. mice (LSHTM breeding colony) were maintained under specific pathogen free conditions 98 
in individually ventilated cages and exposed to 12 hour light – 12 hour dark cycles. Standard 99 
rodent diet (RM No 1 Expanded) and filtered tap water were supplied ad libitum. Mice (6-10 100 
weeks of age at the start of experiments) were infected by intravenous (i.v.) injection of 2 x 107 101 
parasites (L. donovani MHOM/ET/67/HU3) as described (13). Parasites were maintained in 102 
Rag-1 (B6) K.O. mice and amastigotes harvested from spleens >40 days after infection. 103 
BALB/c mice were treated either 14 or 35 days after infection with a single i.v. dose of 104 
AmBisome® in a 0.2 mL bolus injection. On the day of treatment, prior to the administration 105 
of drugs, mice were weighed and randomised into the different treatment groups using a 106 
random number generator. The average weight of mice in each experiment was used for dose 107 
calculations. Untreated groups of mice were included as controls where appropriate. Age 108 
matched uninfected mice were maintained under identical conditions for the same length of 109 
time as their infected comparators. At experimental endpoints mice were weighed and 110 
humanely killed by exsanguination under terminal anaesthesia. Blood was collected by cardiac 111 
puncture in Eppendorf tubes containing heparin and plasma harvested by centrifugation. Livers 112 
and spleens were removed and their weight recorded. Plasma and tissue samples were stored 113 
at -80°C until further processing. For determination of parasite burdens tissue impression 114 
smears were prepared, fixed in 100% methanol and stained in 10% Giemsa. Parasite burden 115 
was determined microscopically and Leishman-Donovan Units (LDUs) calculated by the 116 
formula number of parasites per host cell nucleus x organ weight in mg as described previously 117 
(14). Microscopical evaluation of impression smears was carried out by a scientist unaware of 118 
the treatment allocation.    119 
 120 
Processing of samples for drug quantification. Samples were thawed at room temperature 121 
immediately prior to processing. Livers and spleens were homogenised with an equal volume 122 
of ZrO beads in 4 volumes of 0.1% aqueous formic acid in a Bullet Blender (Next Advance, 123 
UK). For control matrix samples + internal standard (IS), calibration standards, quality control 124 
(QC) samples and study samples 50 µl of tissue homogenate or plasma were diluted with 250µl 125 
IS solution (200 ng/mL tolbutamide in a 84:16 (v/v) mixture of methanol : DMSO). For blank 126 
samples (matrix sample without IS) 50 µl of tissue homogenate or plasma were diluted with a 127 
84:16 (v/v) mixture of methanol: DMSO. After shaking for 10 minutes at 200 rpm at room 128 
temperature dilutions were centrifuged at 4150 x g for 15 minutes at 4oC. Supernatants were 129 
transferred to 96 well plates and stored at -80°C.  130 
 131 
Preparation of calibration standards and QC samples. An amphotericin B stock solution 132 
(1.0 mg/mL) was prepared in DMSO and from that standard spiking solutions were prepared 133 
by serial dilution in 1% SDS in water. Calibration standards at a minimum of 6 concentrations 134 
were prepared by mixing 5 µL of the spiking solutions with 45 µL of blank tissue homogenate 135 
or plasma, matrix matching that of the study samples to be analysed. QC samples at selected 136 
concentrations were prepared in replicate in similar fashion and all samples processed as 137 
described above.   138 
 139 
Preparation of study samples. Concentrations of amphotericin B in study samples varied 140 
widely, depending upon dosing and sampling regimens. Those samples expected to contain 141 
high concentrations of amphotericin B were diluted with matching control matrix by a suitable 142 
factor to reduce their concentration into a quantifiable range (i.e. within the range of calibration 143 
standard concentrations).  144 
 145 
LC/MS analytical conditions. All samples were analysed using an Agilent 1200 HPLC 146 
combined with an Agilent 6410A triple quadrupole mass spectrometer (both Agilent, UK). A 147 
mobile phase of water / 0.1% formic acid (channel A) and methanol / 0.1% formic acid (channel 148 
B) was used to elute sample components from a Kinetex column packed with 5 µm XB-C18 149 
material (2.1mm x 50mm @50°C; Phenomenex, UK). The mobile phase composition was 150 
initially 20% B, programmed to increase linearly to 90% B at 1.60 min. after injection; after 151 
0.4 min. at 90% B the composition was returned to its initial 20% B at 2.10 min. post-injection. 152 
Amphotericin B was detected monitoring the transition m/z 906.5  m/z 743.2, the dehydrated 153 
protonated molecule at m/z 906.5 being the most intense ion produced for this component in 154 
the ion source. 155 
Analyte concentrations were quantified against calibration standards prepared in matched 156 
control matrix, with aliquots of sample and standard being injected typically in the range 1-5 157 
µL, depending on expected study sample concentration.  158 
 159 
Pharmacokinetic analysis. Noncompartmental analysis (NCA) was performed with Phoenix 160 
Win Nonlin v6.3 (Certara, UK). 161 
 162 
Characterisation of serum protein profiles. Blood was collected from L. donovani infected 163 
or uninfected BALB/c mice by cardiac puncture under terminal anaesthesia and stored 164 
overnight at 4ºC. Serum was harvested by centrifugation at 1500 x g, 4ºC for 15 minutes and 165 
stored at -80ºC prior to analysis. Capillary electrophoresis and protein determinations were 166 
carried out by LABOKLIN GmbH&Co.KG (Bad Kissingen, Germany). 167 
 168 
Statistical analysis. Statistical significance between two groups was evaluated by a t-test and 169 
between more than two groups by one-way ANOVA assuming Gaussian distribution, followed 170 
by Sidak’s multiple comparisons test for selected groups as applicable (GraphPad Prism 6). A 171 
p value of ≤ 0.05 was considered statistically significant. 172 
 173 
Ethical statement. Experiments involving animals were carried out under license in 174 
accordance with the Animals (Scientific Procedures) Act 1986 (UK Home Office Project 175 
Licences PPL70/6997 and PPL70/8207) following approval by the Animal Welfare and Ethics 176 
Review Board at LSHTM.   177 
 178 
RESULTS 179 
 180 
Efficacy of single dose liposomal amphotericin B in L. donovani infected BALB/c mice at 181 
two different timepoints after infection. Single dose AmBisome® was administered at doses 182 
of 10 mg/kg, 2.5 mg/kg and 0.6 mg/kg 14 or 35 days after infection. Parasite burden was 183 
evaluated 7 days after dosing. A reproducible decrease in drug efficacy between day 21 and 184 
day 42 post infection was noted in the spleen, which was more pronounced at the lower doses. 185 
In the liver decreased drug efficacy at the lower two doses was noted in one experiment, 186 
whereas in another experiment an increase in drug efficacy was observed at the lowest dose 187 
(Table 1).  188 
 189 
Time-to-kill studies. Single dose AmBisome® was administered to L. donovani infected 190 
BALB/c mice 14 days after infection at doses of 10 mg/kg, 2.5 mg/kg and 0.6 mg/kg. Parasite 191 
burden was evaluated 1, 2, 3 or 7 days after dosing. In the liver effective parasite kill (% 192 
inhibition >90%) was observed 2 days after administration of the highest dose. At the dose of 193 
2.5 mg/kg the hepatic parasite burden was inhibited by >60% at 2 days, >70% at 3 days and 194 
>80% (maximum kill) at 7 days after drug administration. The dose of 0.6 mg/kg was 195 
ineffective (% inhibition <40%) and no change in parasite kill was observed over time (Fig. 196 
1A). A similar pattern of effective kill was observed in the spleen after administration of 10 197 
mg/kg AmBisome® (>80% and >90% inhibition in repeat experiments at 2 days and >90% at 198 
3 days after drug administration) and a static pattern (% inhibition <40%) after administration 199 
of 0.6 mg/kg. Maximum kill at the dose of 2.5 mg/kg varied from 57% to 71% inhibition in 200 
repeat experiments with peaks at 2 and 3 days after drug administration (Fig. 1B). In an 201 
additional experiment L. donovani infected BALB/c mice were treated with a single dose of 202 
2.5 mg/kg AmBisome® 33 days after infection. The hepatic parasite burden was inhibited by 203 
55%, 67% and 62% on days 1, 2 and 3 after drug administration. In the spleen parasite kill was 204 
low on day 1 after drug administration (<40% inhibition) and increased on days 2 and 3 after 205 
drug administration to a maximum of 46% inhibition (Fig. 1C).     206 
 207 
Plasma pharmacokinetics of single dose AmBisome® in L. donovani infected BALB/c 208 
mice. Single dose AmBisome® was administered at dose levels of 10 mg/kg, 2.5 mg/kg and 209 
0.6 mg/kg 14 days after infection. Plasma samples were obtained at 5 minutes, 30 minutes, 1 210 
hour, 3 hours, 6 hours and 24 hours after drug administration, followed by determination of 211 
drug concentrations and estimation of PK parameters. The volume of distribution (Vd) and 212 
clearance (CL) increased with decreasing doses of AmBisome®. The Vd increased from 104 213 
mL/kg at 10 mg/kg to 252 and 681 mL/kg at 2.5 mg/kg and 0.6 mg/kg respectively. The CL 214 
was 27 mL/hr/kg at a dose of 10 mg/kg and 48.1 and 41.9 mL/hr/kg at doses of 2.5 mg/kg and 215 
0.6 mg/kg. The AUC (0-24 hours) was highest at 10 mg/kg (368.5 hr*µg/mL) and lower at 216 
doses of 2.5 mg/kg and 0.6 mg/kg (50.5 and 10.8 hr*µg/mL respectively). PK parameters are 217 
summarised in Table 2.  218 
 219 
Tissue distribution of amphotericin B in L. donovani infected BALB/c mice following 220 
administration of AmBisome® at two different timepoints after infection. Single dose 221 
AmBisome® was administered 14 or 35 days after infection. Amphotericin B concentrations 222 
in plasma, liver and spleen were measured 7 days after dosing. Lower amphotericin B 223 
concentrations were observed in livers and spleens when equal drug doses were administered 224 
on day 35 compared to day 14post infection. When expressed as ng/g tissue drug concentrations 225 
in the liver were 2.6-, 2.2- and 5.6-fold lower on day 42 compared to day 21 post infection at 226 
AmBisome® doses of 10 mg/kg, 2.5 mg/kg and 0.6 mg/kg. Respective tissue concentrations 227 
in the spleen were 4.5-fold, 2.8-fold and 9.6-fold lower. Statistical significance was noted for 228 
the 10 mg/kg dose group (p ≤ 0.0001 for liver, p ≤ 0.01 for spleen). Organ weights significantly 229 
increased from day 21 to day 42 post infection (p ≤ 0.0001 in all dose groups) with a 1.5-fold 230 
increase in the liver and 2.3- to 2.9-fold increases in the spleen. When taking this increase in 231 
organ weights into account and estimating total drug amount / organ the difference between 232 
amphotericin B concentrations on day 21 and day 42 post infection decreased. Differences in 233 
total amphotericin B amount / organ at AmBisome® doses of 10 mg/kg, 2.5 mg/kg and 0.6 234 
mg/kg were 1.7-, 1.5- and 3.8-fold in the liver and 1.5-, 1.3- and 3.9-fold in the spleen. 235 
Statistical significance was noted for the 10 mg/kg dose group in the liver (p ≤ 0.0001). Overall, 236 
higher amphotericin B concentrations were measured in the liver compared to the spleen. Data 237 
is summarised in Table 3A. Amphotericin B concentrations in plasma remained unchanged 238 
when drug was administered on day 14 compared to day 35 post infection. A 0.3-fold difference 239 
was noted in the 0.6 mg/kg dose group, but was not statistically significant (Table 3B).         240 
 241 
Comparative amphotericin B plasma and tissue concentrations in L. donovani infected 242 
and uninfected BALB/c mice 7 days after administration of single dose AmBisome®. 243 
Amphotericin B concentrations were measured in L. donovani infected (14 or 35 days after 244 
infection) and age and husbandry matched uninfected BALB/c mice after administration of 2.5 245 
mg/kg AmBisome®. At both time points amphotericin B concentrations were significantly 246 
lower (p value ≤ 0.0001) in livers and spleens from infected BALB/c mice compared to 247 
uninfected ones. In the liver mean drug concentrations (ng amphotericin B / g tissue) on day 248 
21 and day 42 post infection were 3.5- and 6.5-fold lower in infected compared to uninfected 249 
BALB/c mice. This translated into 2.5- and 5.4-fold differences when taking organ weights 250 
into account and estimating the total amphotericin B amount / organ (Fig. 2A and B). In the 251 
spleen mean amphotericin B concentrations were 29.3- and 100.9-fold lower in infected 252 
compared to uninfected mice on day 21 and day 42 post infection. Respective organ weight 253 
adjusted differences were 10.3- and 16.5-fold (Fig. 2C and D). The opposite was observed in 254 
plasma and significantly higher amphotericin B concentrations measured in infected BALB/c 255 
mice compared to uninfected ones, with 2- and 1.9-fold differences on day 21 (p value ≤ 0.01) 256 
and day 42 (p value ≤ 0.001) post infection (Fig. 2E). Tabulated results are provided in 257 
Supplementary Table S1. 258 
To investigate if differences in amphotericin B levels were also observed after administration 259 
of higher drug doses L. donovani infected (day 33 post infection) or uninfected BALB/c mice 260 
were treated with a single dose of 40 mg/kg AmBisome®. In line with above results 261 
amphotericin B concentrations were significantly lower (p value < 0.0001) in livers and spleens 262 
from infected BALB/c mice compared to uninfected ones. However, plasma concentrations 263 
were similar between the two different groups (p value > 0.05). Data is shown in 264 
Supplementary Table S1. 265 
 266 
Comparative amphotericin B plasma and tissue concentrations in L. donovani infected 267 
and uninfected BALB/c mice up to 48 hours after administration of single dose 268 
AmBisome®. A single dose of 2.5 mg/kg AmBisome® was administered to L. donovani 269 
infected (day 33 post infection) and age and husbandry matched uninfected BALB/c mice. 270 
Plasma and tissue samples were collected 5 minutes, 4 hours, 24 hours and 48 hours after drug 271 
administration and amphotericin B concentrations determined. Amphotericin B plasma levels 272 
decreased within 24 hours in uninfected and L. donovani infected BALB/c mice and remained 273 
at similar levels at 24 and 48 hours after drug administration (Fig. 3A and B). An increase in 274 
amphotericin B concentration was observed in livers and spleens of uninfected BALB/c mice 275 
from 5 minutes to 4 hours after drug administration. Amphotericin B concentrations at 24 and 276 
48 hours after drug administration were comparable to those measured at 4 hours (Fig. 3C and 277 
E). A different kinetic was observed in L. donovani infected BALB/c mice. In the liver a small 278 
increase in amphotericin B concentration was noted from 5 minutes to 4 hours after drug 279 
administration, followed by a decrease at 24 hours and, most notably, 48 hours after drug 280 
administration (Fig. 3D). In the spleen amphotericin B concentrations decreased over the whole 281 
observation period with no increase noted (Fig. 3F). Similar kinetics were observed when 282 
estimating total drug amount per organ (Fig. 3 G – J). Tabulated results are provided in 283 
Supplementary Table S2.      284 
 285 
Host responses to infection. Serum samples from L. donovani infected (day 14 and 43 post 286 
infection) and age and husbandry matched uninfected BALB/c mice were subjected to 287 
electrophoresis and protein determination. Significant differences (p ≤ 0.05) in serum protein 288 
profiles were identified. In infected BALB/c mice serum concentrations of total protein (46.8 289 
+/- 0.6 vs. 56.6 +/- 1.0 g/L), alpha globulin (6.7 +/- 0.2 vs. 8.5 +/- 0.2 g/L) and gamma globulin 290 
(7.6 +/- 0.2 vs. 16.1 +/- 1.0 g/L; 16.3 +/- 0.5 vs. 28.4 +/- 1.3 %) increased from day 14 to day 291 
43 post infection. At the same time % albumin levels decreased (61.4 +/- 0.7 vs. 49.3 +/- 1.1), 292 
but no significant difference was found when comparing total albumin. The albumin:globulin 293 
ratio decreased from day 14 to day 43 post infection ( 1.6 +/- 0.0 vs. 1.0 +/- 0.0). Compared to 294 
uninfected BALB/c mice higher levels of total protein (56.6 +/- 1.0 vs. 47.6 +/- 0.8 g/L), alpha 295 
globulin (8.5 +/- 0.2 vs. 7.3 +/- 0.2 g/L) and gamma globulin (16.1 +/- 1.0 vs. 6.5 +/- 0.2 g/L; 296 
28.4 +/- 1.3 vs. 13.6 +/- 0.2 %) were measured in L. donovani infected mice on day 43 post 297 
infection. At the same timepoint infected BALB/c mice had lower levels of albumin (27.8 +/- 298 
0.4 vs. 29.9 +/- 0.5 g/L; 49.3 +/- 1.1 vs. 62.8 +/- 1.6 %) than uninfected ones. On day 14 post 299 
infection increased levels of % gamma globulin were noted in infected compared to uninfected 300 
BALB/c mice (16.3 +/- 0.5 vs. 12.3 +/- 0.6). On day 43 post infection infected BALB/c mice 301 
had a lower albumin:globulin ratio than uninfected ones (1.0 +/- 0.0 vs. 1.7 +/- 0.1). Data is 302 
summarised in Table 4.         303 
 304 
DISCUSSION 305 
The pharmacodynamics (PD) and pharmacokinetics (PK) of current anti-leishmanial drugs 306 
have yet to be fully established in preclinical disease models. Here we investigated the potency 307 
and biodistribution of AmBisome® in EVL after administration of three different single doses 308 
and at two different timepoints. AmBisome® was well tolerated at all doses administered and 309 
no signs of drug toxicity noted, based on observations of weight, fur condition, behaviour and 310 
facial expression. We also determined the PK profile of AmBisome® in plasma of L. donovani 311 
infected BALB/c mice in an exploratory study and compared trends to published data in 312 
uninfected mice. The observed increase in Cmax and AUClast and the decrease in Vd and CL 313 
with increasing doses is in line with this data (7).  314 
After infection of BALB/c mice with L. donovani the parasite burden in the liver rapidly 315 
increases for the first 2-4 weeks, followed by a decrease in parasite numbers and resolution of 316 
infection. In the spleen the parasite burden increases from 2 weeks after infection and parasite 317 
persistence is observed (15-17). Considering this organ-specific pattern of parasite growth is 318 
important when analysing drug efficacy and potency data. In the spleen drug efficacy was 319 
evaluated against an increasing parasite burden at both time points and a decrease in potency 320 
observed when drug was administered on day 35 compared to day 14 post infection. However, 321 
the magnitude of decrease and the dose at which this occurred differed between experiments. 322 
It is notable that the decrease in drug concentrations / total drug amounts in the spleen following 323 
administration of the same dose of AmBisome® on day 14 vs. day 35 post infection was less 324 
pronounced in the third compared to the second experiment presented in Table 1 325 
(Supplementary Table S3). This may explain the lack of decreased drug potency observed in 326 
experiment 3. In the liver opposing trends were observed at the lowest dose. However, data 327 
obtained in the liver on day 42 post infection is not indicative of direct drug kill only, it reflects 328 
a mixture of parasite killing by drug and a mature granulomatous host response resolving the 329 
infection (18-20). Hence, these opposing trends at a dose which lacked meaningful anti-330 
leishmanial drug efficacy, likely reflect differences in the efficiency of host response rather 331 
than in drug potency.  332 
In parallel to evaluating drug potencies we determined amphotericin B concentrations in 333 
plasma, livers and spleens of infected BALB/c mice at the two different time points and 334 
estimated the total drug amount per organ. In livers and spleens lower drug concentrations and 335 
total drug amounts per organ were noted when drug was administered on day 35 compared to 336 
day 14 post infection  and the difference was highest at the lowest dose. The magnitude of 337 
difference was lower for absolute (organ weight-adjusted) values than for relative values, 338 
which suggests that differences in drug levels between the two time points can partly be 339 
explained by the infection-associated increase in organ weights. A combined effect of organ 340 
enlargement and other pathology-associated factors on drug distribution following 341 
administration of AmBisome® to L. donovani infected BALB/c mice is also supported by 342 
comparative studies in infected and uninfected mice. Again the magnitude of decrease in 343 
amphotericin B levels in livers and spleens of infected mice was lower when organ weight-344 
adjustment was applied, but remained significant and increased from day 21 to day 42 post 345 
infection in both organs. Interestingly, plasma levels of amphotericin B were higher in infected 346 
compared to uninfected mice at this point.    347 
To gain further insight into the kinetics of parasite kill and drug distribution we next examined 348 
drug potency and distribution at multiple and earlier time points after drug administration. The 349 
highest dose of 10 mg/kg AmBisome® exerted maximum kill within 48 hours of drug 350 
administration. This window of time is consistent with drug distribution from blood to tissues 351 
within 24 hours of drug administration, also observed in uninfected mice and other disease 352 
models (21, 22), and a fast rate of parasite kill. Differences in amphotericin B levels between 353 
L. donovani infected and uninfected tissues were also observed at earlier time points. 354 
Importantly, these were indicative of organ-specific drug distribution and elimination in EVL. 355 
Most notable was a lack of drug accumulation over time in L. donovani infected spleens. It is 356 
currently not known to which extent the liposomal formulation contributes to the observed 357 
differences. Comparative biodistribution studies between single dose AmBisome® and 358 
Fungizone®, another clinically used non-liposomal amphotericin B formulation, are hampered 359 
by the toxicity of Fungizone®. The maximum tolerated dose of 1mg/kg (i.v. bolus 360 
administration) of this formulation precludes dosing at clinically meaningful dose levels (23).    361 
Changes in drug distribution under pathological conditions have been reported for a number of 362 
anti-microbials (9, 11, 12, 22, 24-27) and increased drug concentrations at inflammatory sites 363 
believed to result from capillary endothelial damage and recruitment of drug-containing 364 
phagocytic cells to sites of infection. However, tissue penetration of drugs is governed by a 365 
number of factors, which include drug formulation, plasma protein binding and underlying 366 
disease (12). In EVL different pathophysiological features are observed in the liver and spleen. 367 
In the liver a Th1 dominated granulomatous response is characterised by an influx of T cells, 368 
B cells, NK cells and monocytes, with a peak in the inflammatory response around 4 weeks 369 
after infection (18-20). Kupffer cells (KCs), which in uninfected mice line the sinusoids and 370 
form a uniformly distributed phagocytic network, are recruited into the core of the granuloma 371 
in infected mice. Isolated KCs remaining in the sinusoidal network of infected mice have a 372 
reduced cell volume (28), and loss of membrane activity of KCs has been reported within 2 373 
hours of infection with L. donovani (29). Infection of the spleen is characterised by a 374 
breakdown of marginal zone architecture, loss of marginal zone macrophages (MZMs) and 375 
repositioning of marginal metallophilic macrophages (MMMs) (30), an increase in the number 376 
of red pulp macrophages (31), destruction of the follicular dendritic cell and the gp38+ 377 
fibroblastic reticular cell networks (15), and substantial changes to the vascular network 378 
including sprouting of α-SMA+ vessels with active endothelial cell proliferation (32).  379 
Following intravenous administration, liposomes interact with blood proteins and an inverse 380 
relationship between the amount of protein bound and liposome clearance rate from blood has 381 
been demonstrated (33). Here we show that chronically infected BALB/c mice display an 382 
increase in serum gamma globulin and, to a lesser extent, alpha globulin, and a decrease in 383 
albumin. Some of these proteins have been implicated in lipid-protein interactions (34, 35), 384 
which may account for different rates in the distribution of AmBisome® from blood to tissues 385 
between infected and uninfected mice. From the bloodstream liposomes distribute to highly 386 
perfused tissues such as the liver and spleen, which regulate drug elimination (34), and cells of 387 
the mononuclear phagocyte system (MPS) play a major role in this distribution (36). In the 388 
liver also hepatocytes can participate in the uptake and metabolism of small and 389 
phosphatidylcholine-based liposomes (37, 38), which is linked to their ability to exit 390 
fenestrated vessels in this organ (34). In uninfected mice the diameter of liver sinusoidal 391 
endothelial cell (LSEC)-fenestrae is on average 99 +/- 18 nm (39), which would allow 392 
AmBisome® with a mean diameter of <100 nm (7) to pass through. However, fenestrae are 393 
dynamic structures, which may undergo changes in response to local external stimuli (39) and 394 
the impact of L. donovani infection on fenestration is as yet unknown. In the spleen of 395 
uninfected mice most of the blood flows through the marginal zone (40) and MZMs display 396 
preferential uptake of clodronate liposomes over other phagocytic cells in the spleen (41). It is 397 
currently unknown if there are also differences in the extent of drug uptake between the 398 
different cell types for AmBisome®. Future studies, utilising advanced techniques to 399 
simultaneously image drug and cells, are needed to shed light on the spatial distribution of drug 400 
in healthy and diseased organs over time (42).  401 
Gershkovich et al. (9) hypothesised that reduced phagocytic activity of macrophages in EVL 402 
or increased drug elimination, either through leaking capillaries in inflamed tissue or binding 403 
of drug to fragments of killed parasites, may explain the differences in drug levels between 404 
infected and uninfected tissues. Whilst the latter hypothesis cannot be ruled out it is unlikely 405 
to fully account for the lack of drug accumulation in the spleen. Our data favours a model in 406 
which i) increases in organ mass lead to decreased total drug amounts / organ, ii) increased 407 
elimination and / or metabolism is the predominant feature in the liver and iii) drug distribution 408 
to the spleen is progressively decreased during EVL.  409 
A retrospective analysis of risk factors for VL relapse following treatment of patients with 20 410 
mg/kg AmBisome®, administered as 4 doses of 5 mg/kg, in India showed that a slower 411 
decrease in splenomegaly during treatment, but not spleen size at admission, was significantly 412 
associated with relapse (43). In L. donovani infected BALB/ mice the granulomatous response 413 
in the liver appears to follow many of the characteristics observed in subclinical human 414 
infection, whereas the spleen shows hallmarks of progressive human disease (44). However, it 415 
is currently unknown if the differences we observed in AmBisome® distribution and 416 
elimination in this experimental model also exist at different stages in human VL. Nonetheless, 417 
understanding the mechanisms of how the pathophysiology of EVL affects drug absorption, 418 
distribution, metabolism and elimination (ADME) will improve the development and use of 419 
anti-leishmanial drugs and drug delivery systems.  420 
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Table 1.  
  Percentage reduction parasite burden (mean +/- SEM) 
  Liver Spleen 
Expt. Dose Day 21 p.i. Day 42 p.i. Significance Day 21 p.i. Day 42 p.i. Significance 
1 10 mg/kg 99 +/- 0 98 +/- 1 n.s. 99 +/- 0 83 +/- 4 p ≤ 0.05 
 2.5 mg/kg 78 +/- 2 78 +/- 5 n.s. 53 +/- 6 5 +/- 5 p ≤ 0.0001 
 0.6 mg/kg 21 +/- 8 41 +/- 4 p ≤ 0.01 44 +/- 6 4 +/- 4 p ≤ 0.0001 
        
2 2.5 mg/kg 81 +/- 2 80 +/- 3 n.s. 71 +/- 2 36 +/- 11 p ≤ 0.05 
        
3 10 mg/kg 100 +/- 0 99 +/- 1 n.s. 99 +/- 0 93 +/- 2 n.s. 
 2.5 mg/kg 94 +/- 1 80 +/- 5 p ≤ 0.05 40 +/- 6 45 +/- 7 n.s. 
 0.6 mg/kg 54 +/- 3 22 +/- 7 p ≤ 0.0001 38 +/- 10 16 +/- 9 n.s. 
        
  Parasite burden (LDU, mean +/- SEM) in untreated control groups 
1 N/A 966 +/- 66 518 +/- 48 p ≤ 0.01 88 +/- 8 118 +/- 15 n.s. 
2 N/A 415 +/- 32 176 +/- 11 p ≤ 0.001 18 +/- 1 53 +/- 8 p ≤ 0.01 
3 N/A 682 +/- 54 194 +/- 44 p ≤ 0.001 18 +/- 2 84 +/- 9 p ≤ 0.001 
  
Efficacy of single dose AmBisome® in L. donovani infected BALB/c mice.  
Parasite burden was evaluated 7 days after drug administration on day 21 or 42 post infection (p.i.) and is given as mean +/- standard error of the 
mean (SEM). Expt. refers to the number of separate experiments, n.s. not significant, LDU Leishman-Donovan Units.  
 
 
  
Table 2. 
 
  Single i.v. dose of AmBisome® administered: 
PK parameter Unit 10 mg/kg 2.5 mg/kg 0.6 mg/kg 
t1/2 Hr 3.4 5.0 NQ 
Tmax Hr 0.08 0.08 0.08 
Cmax ug/mL 240.3 29.8 3.3 
AUClast hr*ug/mL 368.5 50.5 10.8 
CL mL/hr/kg 27.0 48.1 41.9 
Vd mL/kg 104 252 681 
 
Pharmacokinetic profile of single dose AmBisome® in plasma of L. donovani infected 
BALB/c mice.  
Mice had been infected for 14 days at the time of dosing. Parasite burden in untreated controls 
(mean +/- standard deviation) was 644 +/- 25 LDU in the liver and 17 +/- 1 LDU in the spleen 
(n=3). Data is representative of two separate experiments (n = 1 mouse / timepoint). NQ not 
quoted.  
 
 
 
 
 
 
 
 
 
 
 
  
Table 3. 
A) 
 Amphotericin B concentration [ng/g tissue], mean ± SD Ratio Significance 
 Liver Spleen Liver Spleen Liver Spleen 
Treatment group  Day 21 p.i. Day 42 p.i. Day 21 p.i. Day 42 p.i. Day 21 vs. Day 42 p.i. Day 21 vs. Day 42 p.i. 
AmBisome 10 mg/kg  115 733 +/- 19 582 44 232 +/- 6 900 19 233 +/- 8 600 4 266 +/- 1 399 2.6 4.5 p ≤ 0.0001 p ≤ 0.01 
AmBisome 2.5 mg/kg 12 220 +/- 1 308 5 492 +/- 862 1 770 +/- 412 624 +/- 205 2.2 2.8 n.s. n.s. 
AmBisome 0.6 mg/kg 1 430 +/- 923 257 +/- 58 490 +/- 146 51 +/- 12 5.6 9.6 n.s. n.s. 
         
 Organ weights [mg], mean ± SD Ratio Significance 
AmBisome 10 mg/kg  998 +/- 79 1 532 +/- 98 170 +/- 35 492 +/- 66 0.7 0.3 p ≤ 0.0001 p ≤ 0.0001 
AmBisome 2.5 mg/kg 1 068 +/- 51 1 544 +/- 86 288 +/- 29 654 +/- 70 0.7 0.4 p ≤ 0.0001 p ≤ 0.0001 
AmBisome 0.6 mg/kg 1 070 +/- 82 1 580 +/- 67 286 +/- 23 698 +/- 50 0.7 0.4 p ≤ 0.0001 p ≤ 0.0001 
         
 Estimated amphotericin B amount [ng / organ], mean ± SD Ratio Significance 
AmBisome 10 mg/kg  114 548 +/- 12 631 67 456 +/- 9 000 3 071 +/- 699 2 046 +/- 455 1.7 1.5 p ≤ 0.0001 n.s. 
AmBisome 2.5 mg/kg 12 907 +/- 1 308 8 494 +/- 1 504 522 +/- 79 417 +/- 171 1.5 1.3 n.s. n.s. 
AmBisome 0.6 mg/kg 1 524 +/- 985 404 +/- 85 138 +/- 29 35 +/- 8 3.8 3.9 n.s. n.s. 
 
B) 
 Amphotericin B concentration [ng/mL plasma], mean ± SD Ratio Significance 
Treatment group  Day 21 Day 42 Day 21 vs. Day 42 Day 21 vs. Day 42 
AmBisome 10 mg/kg  191 +/- 23 216 +/- 47 0.9 n.s. 
AmBisome 2.5 mg/kg 116 +/- 18 129 +/- 28 0.9 n.s. 
AmBisome 0.6 mg/kg 5 +/- 5 16 +/- 9 0.3 n.s. 
 
Tissue and plasma concentrations of amphotericin B in L. donovani infected BALB/c mice 7 days after administration of single dose 
AmBisome®.  
Amphotericin B concentrations were determined 7 days after drug administration on day 21 or day 42 post infection (p.i.) in livers and spleens (A) 
and plasma (B). Data is presented as group mean (n = 5 mice / group) +/- standard deviation (SD). Ratios were calculated as follows: mean drug 
concentration Day 21 p.i. / mean drug concentration Day 42 p.i.. Total amphotericin B concentrations / organ were calculated for individual mice 
as follows: organ weight in g (as determined at sacrifice) * amphotericin B concentration in ng/g tissue (as measured after processing of whole 
organs). N.s. not significant. Drug concentrations presented here were determined in the same samples as drug potency was evaluated in experiment 
3 in Table 1.    
 
 
 
 
 
 
 
 
 
Table 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Serum protein profile in L. donovani infected and uninfected BALB/c mice. 
BALB/c mice (n = 6-7 / group) were infected with L. donovani for 14 days (Infected Day 14) or 43 days (Infected Day 43) or left uninfected, but 
maintained under identical conditions as infected ones (Uninfected Day 14 and Uninfected Day 43). Data is presented as mean +/- standard error 
of the mean (SEM). Parasite burden (mean +/- standard deviation) in infected livers was 396 +/- 61 and 273 +/- 52 LDU on day 14 and day 43 
post infection, and in infected spleens 8 +/- 2 and 93 +/- 18 respectively. Values indicated with the same letter (a, b or c) are significantly different 
(p ≤0.05).  
 Infected Day 14 Uninfected Day 14 Infected Day 43 Uninfected Day 43 
Total protein [g/L] 46.8 +/- 0.6a 46.2 +/- 0.6 56.6 +/- 1.0a,b 47.6 +/- 0.8b 
Albumin [g/L] 28.7 +/- 0.4 29.5 +/- 0.6 27.8 +/- 0.4b 29.9 +/- 0.5b 
Albumin % 61.4 +/- 0.7a 64.0 +/- 1.1 49.3 +/- 1.1a,b 62.8 +/- 1.6b 
Alpha globulin [g/L] 6.7 +/- 0.2a 6.8 +/- 0.2 8.5 +/- 0.2a,b 7.3 +/- 0.2b 
Alpha globulin % 14.4 +/- 0.3 14.7 +/- 0.4 15.1 +/- 0.3 15.3 +/- 0.3 
Beta globulin [g/L] 3.7 +/- 0.3 4.2 +/- 0.4 4.1 +/- 0.1 4.0 +/- 0.8 
Beta globulin % 7.9 +/- 0.5 9.0 +/- 0.7 7.2 +/- 0.2 8.2 +/- 1.6 
Gamma globulin [g/L] 7.6 +/- 0.2a 5.7 +/- 0.3 16.1 +/- 1.0a,b 6.5 +/- 0.2b 
Gamma globulin % 16.3 +/- 0.5a,c 12.3 +/- 0.6c 28.4 +/- 1.3a,b 13.6 +/- 0.2b 
Albumin:globulin ratio 1.6 +/- 0.0a 1.8 +/- 0.1 1.0 +/- 0.0a,b 1.7 +/- 0.1b 
Fig. 1  
A)           B)  
 
 
C) 
 
 
 
 
 
 
 
 
 
 
 
Time-to-kill of single dose AmBisome® in L. donovani infected BALB/c mice.  
Percentage inhibition of parasite burden in liver (A) and spleen (B) 1, 2, 3 and 7 days after a 
single dose of AmBisome® at dose levels of 10 mg/kg (black bars), 2.5 mg/kg (grey bars) and 
0.6 mg/kg (striped bars). C: Percentage inhibition of parasite burden in liver (black bars) and 
spleen (grey bars) 1, 2 and 3 days after a single dose of 2.5 mg/kg AmBisome®. Treatment 
was given 14 days (A and B) or 33 days (C) after infection. Data are presented as group mean 
(n=5), error bars represent standard error of the mean (SEM). Data in A and B is representative 
of two separate experiments.  
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p ≤ 0.01 
p ≤ 0.001 
p ≤ 0.0001 p ≤ 0.0001 p ≤ 0.0001 p ≤ 0.0001 
p ≤ 0.0001 p ≤ 0.0001 
p ≤ 0.0001 p ≤ 0.0001 
Comparative plasma and tissue concentrations in L. donovani infected and uninfected 
BALB/c mice 7 days after administration of single dose AmBisome®. 
Amphotericin B concentrations were measured on day 21 or day 42 post infection (Infected - 
day 21, Infected – day 42) and in uninfected BALB/c mice, maintained under identical 
conditions (Uninfected - day 21, Uninfected – day 42). Amphotericin B concentrations are 
presented as ng/g tissue (A, C) or ng / organ (B, D) in livers (A, B) and spleens (C, D) and as 
ng/mL in plasma (E). Each symbol represents data from an individual mouse. Horizontal lines 
indicate the mean (n = 4-5 mice / group) and error bars standard deviations (SD). Total 
amphotericin B concentrations / organ were calculated for individual mice as follows: organ 
weight in g (as determined at sacrifice) * amphotericin B concentration in ng/g tissue (as 
measured after processing of whole organs). Tissue concentrations in infected mice were 
measured in samples from experiment 3 in Table 1. Data is representative of two separate 
experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 
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C)       D) 
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E)      F) 
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G)        H) 
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Comparative plasma and tissue concentrations in L. donovani infected and uninfected 
BALB/c mice up to 48 hours after administration of single dose AmBisome®.  
AmBisome® was administered to BALB/c mice, naive (A, C, E, G, I) or infected with L. 
donovani for 35 days (B, D, F, H, J) and amphotericin B concentrations determined in plasma 
(A, B), liver (C, D, G, H) and spleen (E, F, I, J) at 5 minutes, 4 hours, 24 hours or 48 hours 
after drug administration. Amphotericin B concentrations are presented as ng/g tissue (C – F) 
or total amphotericin B concentration / organ (G – J). Total amphotericin B concentrations / 
organ were calculated as follows: organ weight in g (as determined at sacrifice) * amphotericin 
B concentration in ng/g tissue (as measured after processing of whole organs). Each symbol 
represents data from an individual mouse. Horizontal lines indicate the mean (n = 3 / group) 
and error bars standard deviation (SD).   
